Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: J Thromb Haemost. 2018 Mar 13;16(4):670–679. doi: 10.1111/jth.13974

Table 4.

Hazard ratios (95% CI) of incident AF after VTE, overall and by type of VTE: The Atherosclerosis Risk in Communities Study, 1987-2011

No VTE (n=14,516) VTE (n=613)
# AF Events 2,048 62
Person-years 279,785 2,990
Incidence Rate (95% CI)* 7.3 (7.0-7.6) 20.7 (16.0-26.4)
Hazard ratio (95% CI)
 Model 1 1 (REF) 1.94 (1.50-2.50)
 Model 2 1 (REF) 1.73 (1.34-2.24)
 Model 3 1 (REF) 1.20 (0.91-1.57)
No VTE (n=14,858) Any PE (n=271)
# AF Events 2,090 20
Incidence Rate (95% CI)* 7.4 (7.1-7.7) 16.4 (10.4-24.9)
Hazard ratio (95% CI)
 Model 1 1 (REF) 1.44 (0.93-2.24)
 Model 2 1 (REF) 1.29 (0.83-2.01)
 Model 3 1 (REF) 0.73 (0.46-1.16)
No VTE (n=14,787) DVT only (n=342)
# AF Events 2,068 42
Incidence Rate (95% CI)* 7.4 (7.0-7.7) 23.7 (17.3-31.7)
Hazard ratio (95% CI)
 Model 1 1 (REF) 2.28 (1.68-3.10)
 Model 2 1 (REF) 2.05 (1.50-2.78)
 Model 3 1 (REF) 1.61 (1.18-2.21)
*

Incidence rate is per 1000 person-years.

Includes events presenting as PE alone, and those presenting as both DVT and PE.

CI, confidence interval; AF, atrial fibrillation; VTE, venous thromboembolism.

Model 1 is adjusted for age, sex and race-field center.

Model 2: Model 1+ income, education, physical activity, smoking, waist circumference, height, systolic blood pressure, anti-hypertensive medication, diabetes, prevalent coronary heart disease, prevalent heart failure, prevalent anticoagulant use and eGFR.

Model 3: Model 2 + time-dependent anticoagulant use.